Glucotrack, Inc.
GCTK- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001506983
No open-market purchases or sales by Glucotrack, Inc. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $187.1K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Glucotrack, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Glucotrack, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Balo Andrew K | Director | 4,692 | Oct 7, 2025 | 1 |
| Malave Luis | Director | 4,058 | Oct 7, 2025 | 1 |
| Goode Paul | Chief Executive Officer | 339 | Oct 7, 2025 | 1 |
| Carter Erin Catherine | Director | 2,148 | Oct 7, 2025 | 1 |
| Ballantyne John | Director, 10% Owner | 4,126 | Mar 31, 2025 | 0 |
| John A. Ballantyne Revocable Living Trust dated 08/01/2017 | 10% Owner | 2,743,591 | Mar 31, 2025 | 0 |
| Fischell Robert | Director | 2,045 | Mar 28, 2025 | 0 |
| Danzig Allen | Director | 1,922 | Mar 28, 2025 | 0 |
| Sycoff Drew | Director, 10% Owner | 2,951,258 | Jul 3, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 (view filing)8:17 AM ET | Jul 18, 2024 | 256 daysLate | Malave LuisDirector | PPurchaseCommon Stock, par value $0.001 per share | +6.41K | – | – | – | DerivativePrice outlier |
| Mar 31, 2025 (view filing)7:52 AM ET | Jul 18, 2024 | 256 daysLate | Carter Erin CatherineDirector | PPurchaseCommon Stock, par value $0.001 per share | +1.60K | – | – | – | DerivativePrice outlier |
| Mar 31, 2025 (view filing) | Jul 30, 2024 | 244 daysLate | John A. Ballantyne Revocable Living Trust dated 08/01/201710% Owner | PPurchaseCommon Stock, par value $0.001 per share | +242.1K | – | – | –59.3K after | Derivative3 lotsDuplicate filing |
| Mar 31, 2025 (view filing) | Jul 30, 2024 | 244 daysLate | Ballantyne JohnDirector, 10% Owner | PPurchaseCommon Stock, par value $0.001 per share | +242.1K | – | – | –59.3K after | Derivative3 lots |
| Mar 28, 2025 (view filing)9:43 PM ET | Jul 1-18, 2024 | 270 daysLate | Goode PaulChief Executive Officer | PPurchaseCommon Stock, par value $0.001 per share | +2.42K | – | – | – | Derivative2 lots |
| Jul 3, 2024 (view filing) | Jul 1 | 2 days | Sycoff DrewDirector, 10% Owner | PPurchase | +138.0K | – | – | –138.0K after | Derivative |
| Jul 3, 2024 (view filing) | Jul 1 | 2 days | Goode PaulChief Executive Officer | PPurchase | +42.0K | – | – | –42.0K after | Derivative |
| Apr 24, 2024 (view filing) | Apr 22 | 2 days | Sycoff DrewDirector, 10% Owner | PPurchase | +182.5K | $1.26 | +$230.0K | +6.6%2.95M after |